Biotech Active Stocks: Celgene Corporation (NASDAQ:CELG), Arena Pharmaceuticals (NASDAQ:ARNA), Cell Therapeutics (NASDAQ:CTIC), Inovio Pharmaceuticals (NYSEMKT:INO)

Technology Stocks News 2

U.S. health regulators on Friday approved a Celgene Corporation (NASDAQ:CELG) drug to treat psoriatic arthritis, a type of arthritis associated with the skin disease psoriasis that causes joint pain, stiffness and swelling. Celgene Corporation (NASDAQ:CELG) stock performance was -3.74% in last session and finished the day at $144.40. Traded volume was 9.50million shares in the last session and the average volume of the stock remained 3.20million shares. The beta of the stock remained 0.88. Celgene Corporation (NASDAQ:CELG) insider ownership is 0.20%.

Arena Pharmaceuticals Inc (NASDAQ:ARNA) saw some unusual options trading activity on Friday. Investors purchased 18,110 call options on the company, AmericanBankingNews.com reports. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) dropped -2.54 percent to $6.15 Friday on volume of 9.85million shares. The intra-day range of the stock was $6.03 to $6.35. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has a market capitalization of $1.35billion.

Cell Therapeutics Inc (NASDAQ:CTIC) CEO James A. Bianco sold 395,000 shares of Cell Therapeutics Inc (NASDAQ:CTIC) stock in a transaction dated Friday, March 21st. The stock was sold at an average price of $3.83, for a total transaction of $1,512,850.00. Cell Therapeutics Inc (NASDAQ:CTIC)’s stock on Mar 21, 2014 reported a decrease of -1.55% to the closing price of $3.81. Its fifty two weeks range is $0.97-$4.25. The total market capitalization recorded $570.142million. The overall volume in the last trading session was 9.95million shares. In its share capital, CTIC has 131.13million outstanding shares.

Inovio Pharmaceuticals Inc (NYSEMKT:INO) is heading towards an important event as mentioned by its CEO Dr. Joseph Kim during the earnings call, which took place on Monday. This event relates to the company’s mid-stage data readout for its lead clinical candidate, VGX-3100, which is considered as a potential vaccine for HPV-caused cancers and pre-cancers. On Friday, shares of Inovio Pharmaceuticals Inc (NYSEMKT:INO) dropped -2.89% to close the day at $3.69. Company return on investment (ROI) is -68.30% and its monthly performance is recorded as 27.24%. Inovio Pharmaceuticals Inc (NYSEMKT:INO) quarterly revenue growth is 71.63%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone